{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=ACZ885+150+mg+%28Canakinumab%29", "query": { "intervention": "ACZ885 150 mg (Canakinumab)" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 26, "total_pages": 3, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=ACZ885+150+mg+%28Canakinumab%29&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-10-04T14:23:58.259Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02296424", "title": "ß-SPECIFIC 4 Patients: Study of Pediatric EffiCacy and Safety wIth FIrst-line Use of Canakinumab", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Systemic Juvenile Idiopathic Arthritis (SJIA)" ], "interventions": [ { "name": "ACZ885 150 mg (Canakinumab)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "20 Years", "sex": "ALL", "summary": "2 Years to 20 Years" }, "enrollment_count": 182, "start_date": "2014-11-17", "completion_date": "2017-09-25", "has_results": true, "last_update_posted_date": "2019-07-09", "last_synced_at": "2026-10-04T14:23:58.259Z", "location_count": 2, "location_summary": "Los Angeles, California • Columbus, Ohio", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT02296424" }, { "nct_id": "NCT00886769", "title": "Single-dose Study to Assess Efficacy of Canakinumab (ACZ885) in Patients With Active Juvenile Idiopathic Arthritis (SJIA)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Systemic Juvenile Idiopathic Arthritis" ], "interventions": [ { "name": "Canakinumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "19 Years", "sex": "ALL", "summary": "2 Years to 19 Years" }, "enrollment_count": 84, "start_date": "2009-07", "completion_date": "2011-01", "has_results": true, "last_update_posted_date": "2017-03-29", "last_synced_at": "2026-10-04T14:23:58.259Z", "location_count": 15, "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 10 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00886769" }, { "nct_id": "NCT01731990", "title": "Safety, Tolerability and Efficacy of ACZ885 on Leg Artery Structure in Patients With Peripheral Artery Disease", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Peripheral Artery Disease" ], "interventions": [ { "name": "Canakinumab (ACZ885)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 38, "start_date": "2012-10-30", "completion_date": "2016-08-04", "has_results": true, "last_update_posted_date": "2025-04-29", "last_synced_at": "2026-10-04T14:23:58.259Z", "location_count": 8, "location_summary": "Phoenix, Arizona • Jacksonville, Florida • Chicago, Illinois + 4 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Lutherville", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01731990" }, { "nct_id": "NCT01431638", "title": "Long-Term Safety and Tolerability of Canakinumab Prefilled Syringes in Frequently Flaring Acute Gouty Arthritis Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Acute Gouty Arthritis" ], "interventions": [ { "name": "Canakinumab 150mg in prefilled syringe", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 397, "start_date": "2011-08-25", "completion_date": "2013-05-09", "has_results": true, "last_update_posted_date": "2021-07-19", "last_synced_at": "2026-10-04T14:23:58.259Z", "location_count": 54, "location_summary": "Anniston, Alabama • Gulf Shores, Alabama • Mobile, Alabama + 50 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Gulf Shores", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT01431638" }, { "nct_id": "NCT04229004", "title": "A Multi-center Trial to Evaluate Multiple Regimens in Metastatic Pancreatic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Metastatic Pancreatic Cancer", "Metastatic Pancreatic Adenocarcinoma" ], "interventions": [ { "name": "Gemcitabine combined with nab-paclitaxel", "type": "DRUG" }, { "name": "Dose -mFOLFIRINOX", "type": "DRUG" }, { "name": "Dose - Pamrevlumab combined with gemcitabine and nab-paclitaxel", "type": "DRUG" }, { "name": "Dose- Canakinumab and Spartalizumab combined with nab-paclitaxel and gemcitabine", "type": "DRUG" }, { "name": "Drug: Dose -SM-88", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pancreatic Cancer Action Network", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 502, "start_date": "2020-01-31", "completion_date": "2025-02-05", "has_results": false, "last_update_posted_date": "2025-04-06", "last_synced_at": "2026-10-04T14:23:58.259Z", "location_count": 25, "location_summary": "La Jolla, California • Los Angeles, California • San Francisco, California + 18 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04229004" }, { "nct_id": "NCT00900146", "title": "Dose Finding, Safety and Efficacy of Monthly Subcutaneous Canakinumab Administration in Metformin Monotherapy Treated Type 2 Diabetic Patients", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "Canakinumab", "type": "DRUG" }, { "name": "Metformin", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "74 Years", "sex": "ALL", "summary": "18 Years to 74 Years" }, "enrollment_count": 556, "start_date": "2009-04", "completion_date": "2010-11", "has_results": true, "last_update_posted_date": "2012-02-20", "last_synced_at": "2026-10-04T14:23:58.259Z", "location_count": 18, "location_summary": "Phoenix, Arizona • La Jolla, California • Los Gatos, California + 15 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Gatos", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Tustin", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00900146" }, { "nct_id": "NCT00995930", "title": "Safety & Effectiveness on Vascular Structure and Function of ACZ885 in Atherosclerosis and Either T2DM or IGT Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Diabetes Mellitus, Type 2", "Atherosclerosis", "Prediabetic State" ], "interventions": [ { "name": "ACZ885", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "74 Years", "sex": "ALL", "summary": "18 Years to 74 Years" }, "enrollment_count": 189, "start_date": "2009-12", "completion_date": "2014-02", "has_results": true, "last_update_posted_date": "2015-06-29", "last_synced_at": "2026-10-04T14:23:58.259Z", "location_count": 2, "location_summary": "New York, New York • Cincinnati, Ohio", "locations": [ { "city": "New York", "state": "New York" }, { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00995930" }, { "nct_id": "NCT01327846", "title": "Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Atherosclerosis" ], "interventions": [ { "name": "Canakinumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Standard of care", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10066, "start_date": "2011-04-11", "completion_date": "2019-04-14", "has_results": true, "last_update_posted_date": "2020-01-22", "last_synced_at": "2026-10-04T14:23:58.259Z", "location_count": 315, "location_summary": "Athens, Alabama • Birmingham, Alabama • Fairhope, Alabama + 248 more", "locations": [ { "city": "Athens", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Fairhope", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT01327846" }, { "nct_id": "NCT00685373", "title": "Efficacy and Safety of ACZ885 in Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Cryopyrin-Associated Periodic Syndromes", "Familial Cold Autoinflammatory Syndrome", "Muckle Wells Syndrome", "Neonatal Onset Multisystem Inflammatory Disease" ], "interventions": [ { "name": "Canakinumab (ACZ885)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Years", "maximum_age": null, "sex": "ALL", "summary": "3 Years and older" }, "enrollment_count": 166, "start_date": "2008-05", "completion_date": "2010-04", "has_results": true, "last_update_posted_date": "2016-11-04", "last_synced_at": "2026-10-04T14:23:58.259Z", "location_count": 6, "location_summary": "Little Rock, Arkansas • San Francisco, California • Columbus, Georgia + 3 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "San Francisco", "state": "California" }, { "city": "Columbus", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00685373" }, { "nct_id": "NCT04795466", "title": "Study of the Efficacy and Safety of Various Anti-inflammatory Agents in Participants With Mild Cognitive Impairment or Mild Alzheimer's Disease", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Mild Cognitive Impairment", "Alzheimer Disease" ], "interventions": [ { "name": "Canakinumab", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "45 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "45 Years to 90 Years" }, "enrollment_count": 34, "start_date": "2021-10-28", "completion_date": "2024-03-07", "has_results": true, "last_update_posted_date": "2025-10-16", "last_synced_at": "2026-10-04T14:23:58.259Z", "location_count": 2, "location_summary": "Charlestown, Massachusetts • Stony Brook, New York", "locations": [ { "city": "Charlestown", "state": "Massachusetts" }, { "city": "Stony Brook", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04795466" } ] }